中国再生医学国际有限公司（股票代码：08158）于2026年3月2日发布2026年2月股份变动月报。公告显示，截至2月28日，公司法定注册股本仍为50亿股（每股面值0.2港元），总面值维持在10亿港元，与上月保持一致。
公司截至2月底的已发行股份总数为304,252,480股，库藏股数为零。本月无新增发行、购回或注销股份活动。期权方面，公司根据新购股权计划（于2025年6月27日获股东大会通过）共授出30,425,248份期权，但2月内未有行使，亦未产生任何行使所得资金。公告确认公司公众持股量符合相关上市规则要求，股本结构维持稳定。公司同时声明遵守香港联交所《上市规则》及其他适用法律法规，公告由公司秘书陈乐彤签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.